Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 2Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 40NET 3Endocrine 3Sarcoma 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Sarcoma 266Osteosarcoma 81Sarcoma, Ewing 50Neoplasms 43Melanoma 43Gastrointestinal Stromal Tumors 43Colorectal Neoplasms 40Breast Neoplasms 37Bone Neoplasms 37Rhabdomyosarcoma 35Neoplasm Metastasis 32Pancreatic Neoplasms 30Ovarian Neoplasms 30Neuroblastoma 30Stomach Neoplasms 28Dendritic Cell Sarcoma, Interdigitating 27Lung Neoplasms 26Liposarcoma 25Leiomyosarcoma 25Glioblastoma 23Uterine Cervical Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Sarcoma, Synovial 21Head and Neck Neoplasms 21Esophageal Neoplasms 21Sarcoma, Kaposi 19Lymphoma 18Carcinoma, Hepatocellular 18Urinary Bladder Neoplasms 17Prostatic Neoplasms 17

Interventions

repotrectinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Digestive System Neoplasms × Sarcoma × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07406633 2026-05-19

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Kumquat Biosciences Inc.

Phase 2 Recruiting
46 enrolled
GastrointestinalSarcoma

Digestive System Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡